Capri EGM Acquires Lab and R&D Facility for Resilience

Capri EGM, an investment company, has funded and acquired a newly constructed, state-of-the-art lab and R&D facility for National Resilience Inc (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. 
 
Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued at as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT). Resilience also has a multi-year agreement to produce mNRA for Moderna’s Covid-19 vaccine, a strategic multi-year R&D alliance with Harvard University to develop complex medicines, and a multi-product biomanufacturing development agreement with Takeda supporting their plasma-derived medicines portfolio.
 
The Resilience Lab & Research build-to-suit is located in North Florida’s Research and Life Science cluster near the University of Florida and the University of Florida’s Innovate Sid Martin Biotech Incubator. 
 
Capri EGM confirms that life science and R&D corporate real estate remain high conviction themes for its ongoing build-to-suit program and investment activity and believes that these types of assets are among the biggest beneficiaries of the developing macroeconomic trends. Capri EGM believes the pandemic has only increased the need for these types of assets and has highlighted their importance. 
 
National Resilience is building a sustainable network of high-tech, end-to-end manufacturing solutions to help ensure medicines can be made quickly, safely, and at scale.